INTRODUCTION
Endovascular treatment has evolved from Charles Dotter's use of coaxial "pencilpoint" dilators to treat superficial femoral artery (SFA) stenosis in 1964 [1] . Revascularization via endovascular treatment is widely used in the cardiovascular field. To correct stenosis or occlusive arterial lesions, new technologies such as excimer laser and rotational and excisional atherectomy have been introduced [2] . Among these debulking technologies, exci sional or directional atherectomy (DA) showed better results than other angioplasty methods in the DEFINITIVE LE study [3] .
Endovascular treatment via radiologic imaging has weak nesses due to the use of 2dimensional (2D) image. DA is a tech nology for removing atheroma from within the lumen. Thus, the results of DA are related to 3dimensional (3D) structures. Optical coherence tomography (OCT) and intravascular ultra sound (IVUS) are good options for analysis of 3D intraluminal vascular structures. However, OCT and IVUS are not yet widely used.
Ultrasonography (USG) is a popular and easytouse method that is a good option for visualizing 3D intraluminal vascular structures. The aim of our study was to determine the useful ness of intraoperative USG during DA and to evaluate the early results of DA using the Silverhawk/Turbohawk System.
METHODS

Patients
This retrospective study was designed to determine the use fulness of USG during DA for patients with femoral artery stenosis at our hospital from January to December 2014.
The indications for this procedure were femoral artery ste no sis, greater than 70% stenosis, and less than 2cm lesion length. Stenotic lesions without calcification were treated with a SilverHawk device, and calcified stenotic lesions were treated with a TurboHawk atherectomy device (Covidien, Mansfield, MA, USA). Computed tomography angiography and USG were performed routinely for preinterventional planning.
Retrospective data collection and analysis were approved by the Institutional Review Board of Samsung Medical Center (IRB No. 201507010).
Procedure
Percutaneous femoral arterial puncture was performed with a retrograde or antegrade approach for the DA procedure. A 7F or 8F sheath was introduced depending on the size of the DA device. Lesions of the stenotic artery were passed using a 0.035inch angled hydrophilic and 0.014inch guidewire. The Silverhawk atherectomy device is composed of a monorail guided catheter using a highspeed cutting blade. The cutting blade was placed in close apposition to the atherosclerotic plaque using a hinge system and was advanced through the lesion to excise the plaque. The device can be rotated 360 degrees to position the cutting blade toward the plaque within the artery. The hinged nose cone located distal to the cutting blade acts as a container for collecting atherosclerotic debris. If a calcified lesion was present, the SpiderFX embolic protection device (Covidien) was used to prevent distal embolization.
Residual luminal stenosis was determined at the end of the DA procedure using digital subtraction angiography and USG ( Fig. 1 ). We did not use any closure devices at the arterial punc ture site. All patients were heparinized during the procedure using intravenous injection of unfractionated heparin (50 IU/kg of body weight), and all patients were medicated with an anti platelet agent during the followup period.
Evaluation of outcome
Technical success was defined as less than 30% residual ste no sis according to angiographic findings and USG. Primary pa tency was defined as no restenosis and a peak systolic velocity ratio (PSVR) less than 3.5 on USG. USG was performed 1 day, 1 month, 6 months, and 1 year after DA.
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RESULTS
There were 20 lesions from 14 patients who were treated with DA using the SilverHawk or TurboHawk atherectomy devices. All of the patients were male, and the median age was 68.5 years (range, 56-86 years). There were 2 patients with a history of balloon angioplasty in the femoral artery (Table 1) . Seventeen cases of noncalcified stenosis were treated with the SilverHawk device, and three calcified lesions were treated with the TurboHawk atherectomy device. There were 18 de novo stenosis lesions and two restenotic lesions ( Table 2) .
Two retrograde and 12 antegrade approaches were used for the procedure. Distal embolic protection (SpiderFX Embolic Protection Device, Covidien) was used for three lesions. There were no cases of pre or postprocedural ballooning or stenting of stenotic lesions. Concomitant common femoral artery (CFA) endarterectomy was conducted in 1 patient (7.1%) during DA. There was one intima dissection that did not require adju vant inter vention, and there were no cases of perforation, pseu doaneurysm, distal embolization, or thrombotic occlusion during the DA procedure. Procedural success (<30% stenosis at the end of the procedure) was 100% according to angiographic findings, but only 30% based on USG findings (Table 3) .
We analyzed the change in ankle brachial index (ABI) after the procedure. Preoperative ABI increased from 0.70 (range, 0.54-1.10) to 0.88 (range, 0.43-1.05) after the procedure. Claudication as an ischemic symptom disappeared after the procedure (Table 4) .
We analyzed the change in restenosis during the followup period (Fig. 2) . According to USG evaluation, median residual stenosis was 40% (range, 28%-42%) at the end of the DA procedure, 40% (range, 30%-55%) at 1 month, 55% (range, 35%-85%) at 6 months, and 64% (range, 60%-100%) at 1 year. One lesion showed total occlusion 10 months after DA. One lesion was treated with stent insertion due to recurrent claudication related to 70% restenosis six months after DA. Primary patency (defined as PSVR ≤ 3.5 with no reintervention for target lesions at 6 months) was observed in 90.0% of patients (18 of 20), and 78.6% of patients (11 of 14) were free of ischemic symptoms such as claudication at 6 months.
DISCUSSION
DA was the debulking method used in the present study, and the SilverHawk Plaque Excision System was used as the prototype excisional atherectomy device. Zeller et al. [4] reported that 131 lesions from 84 patients with Rutherford category 2 to 5 stenosis were treated using the prototype excisional atherectomy device, and the technical success was 86%, while the primary patency rate was 53% at 12.5 months. Recently, the DEFINITIVE LE trial showed a procedural success rate of 89.1%, a device success rate of 74.9%, and a primary patency of 78% at 12 months. Periprocedural adverse events included embolization (3.8%), perforation (5.3%), dissection causing flow limitation (2.3%), abrupt closure (2.0%), and aneurysm (0.4%), and the bailout stent rate was 3.2% [3, 5] .
In our study, the procedure and device success rates were 100% and the 6month primary patency rate was 90.0% on angiography compared to the 87.6% observed in the DEFINITIVE LE study. There were no perforations, pseudoaneurysms, distal embolizations, or thrombotic occlusions in our study.
The main difference between our protocol and other proto cols was the approach for determining residual stenosis at the end of the procedure. In all prior studies, residual stenosis was evaluated at the end of the DA procedure using angiographic findings. In contrast, we determined residual stenosis using both angiography and USG.
The guidelines for the SilverHawk instrument showed pass age of the device through each of the 4 quadrants within the atheroma. Also, residual stenosis at the end of the DA proce dure was determined based on angiography according to the guidelines. However, not all atheromas were symmetrical in shape, so the direction and number of device passages varied.
Angiography revealed only a planar 2D silhouette of the lumen, which does not provide a precise assessment of luminal narrowing. Intravascular imaging enables direct visualization of the arterial wall. Intravascular imaging modali ties show more accurate diagnostic information and evaluation of plaque and vessel remodeling [6] . OCT is an evolving tech nology that uses nearinfrared light to construct an image of the vessel wall. These methods are good tools for planning intervention strategies and angioplasty. However, IVUS is ex pen sive and has a high rate of distal embolization [6] . OCT also requires blood to be cleared from the vessel lumen in order to acquire an image [7] .
USG provides more detailed dimensional information com pared to angiography. There is a distinct possibility that our good results might be related to the use of USG to determine residual stenosis at the end of the procedure compared to tradi tional angiography evaluation.
In our study, there was one case of CFA endarterectomy. This patient had right SFA as well as left iliac and CFA stenosis. This patient was treated via left CFA endarterectomy for the approaching vessel, left iliac stenting and right SFA DA. This is a good example of a hybrid operation strategy.
However, our study did have some limitations. First, our results were based on shortterm followup. Second, this study enrolled only 14 patients, so additional studies with longer followup periods and larger populations are needed.
In conclusion, our results demonstrated that DA using the SilverHawk/TurboHawk system with intraoperative USG is an effective treatment option for short segment occlusive lesions of the femoral artery. USG appears to be a good option for evaluating 3D intraluminal vascular structures. Intraoperative USG during DA might increase the rate of procedural success and decrease the number of complications such as perforation.
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